• Download mobile app
16 Feb 2025, Edition - 3505, Sunday

Trending Now

  • It is because of the Dravidians that the country’s regressive gangs have not been able to rise up – M.K.Stalin, Chief Minister
  • According to RBI statistics, there were 10.8 million credit cards in circulation by December 2024, almost double the number of 5.53 million, 5 years ago.
  • Saying that people are afraid of the Mullaperiyar dam breaking, sounds like a ‘comic’ story”- Supreme Court Justice Rishikesh Roy
  • Bumrah wins ICC Test Cricketer of the Year 2024 award.

Businesswire

Promethera Biosciences: Announcement Regarding Business Activities in Japan

by businesswireindia.com

Share
Business Wire India

Promethera Biosciences SA (Group), a global innovator in cell-based medicines and liver diseases, announced the foundation of a new branch office in Tokyo, Promethera Biosciences Japan Branch Ltd on May, 2018. Establishing a branch office in Japan marks the starting point for building a strong presence of Promethera in Japan first, initially focusing on increased Business Development, Investor Relations activities and expansion of its business and products pipeline in Japan. This presence will also address the Asian markets as a second step.

 

As we develop such business activities, we are considering various options for further strengthening our presence in Japan. These options include future listing on the Tokyo Stock Exchange Market (whether or not using a Japanese Depositary Receipt (JDR scheme*) or another Asian stock exchange, and/or partnering with pharmaceuticals.

 

*for more information of the JDR scheme, please see
https://www.jpx.co.jp/english/equities/listing-on-tse/new/basic/05.html

 

About Promethera Biosciences:

 

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline, we develop antibody technologies such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert (Belgium), Durham (NC, USA), Tokyo (Japan) and Basel (Switzerland).

 

Promethera®, HepaStem®, H2stem®, are all registered trademarks of the PROMETHERA group.

 

 
Source: Businesswire
COIMBATORE WEATHER